Pharsight

Drugs that contain Binimetinib

1. Mektovi patents expiration

MEKTOVI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178693 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(11 months ago)

US7777050 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2024

(17 days from now)

US9562016 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8513293 ARRAY BIOPHARMA INC Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal
Mar, 2023

(11 months ago)

US8193229 ARRAY BIOPHARMA INC Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(11 months ago)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(7 years from now)

US9598376 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(9 years from now)

US9980944 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Oct 11, 2026

Market Authorisation Date: 27 June, 2018

Treatment: Indicated in combination with encorafenib for the treatment of melanoma; Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indi...

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage

MEKTOVI family patents

Family Patents